The present invention describes crystalline form of 5-chloro-N-(2-isopropoxy-5-methyl-4-(piperidin-4-ylphenyl)-N-2-(isopropylsulfonyl)phenyl)-2,4-diamine. The present invention further relates to pharmaceutical compositions comprising said crystalline form, and methods of using said crystalline form and pharmaceutical composition to treat disease.